plevitrexed + topotecan hydrochloride
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fallopian Tube Cancer
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Trial Timeline
Mar 1, 2001 → Feb 1, 2004
NCT ID
NCT00014690About plevitrexed + topotecan hydrochloride
plevitrexed + topotecan hydrochloride is a phase 2 stage product being developed by AstraZeneca for Fallopian Tube Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00014690. Target conditions include Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00014690 | Phase 2 | Completed |
Competing Products
20 competing products in Fallopian Tube Cancer